Clinical trial

Natalizumab (Tysabri) Re-Initiation of Dosing

NCT00297232

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2006-03-01

PhasePHASE3

Study timeline

Study start (unknown)2006-03-01Date precision: month

Registry last updated2016-07-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing-Remitting Multiple Sclerosisunresolved

Interventions

NatalizumabDRUG · verified · RxNorm: natalizumab

Sponsors & collaborators

Biogenlead sponsor

Mapped research locations

BudapestHungary4 LondonUnited Kingdom3 BarcelonaSpain2 ParisFrance2 WarsawPoland2 PragueCzechia2 IstanbulTurkey (Türkiye)2 StockholmSweden2 BialystokPoland2 BrnoCzechia2 DebrecenHungary2 TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00297232 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.